Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Aug 27;1(8):527-532.
doi: 10.1002/acr2.11074. eCollection 2019 Oct.

Patterns of B Cell Repletion Following Rituximab Therapy in a Pediatric Rheumatology Cohort

Chace Mitchell  1 , Courtney B Crayne  1 , Randy Q Cron  1
Affiliations

Patterns of B Cell Repletion Following Rituximab Therapy in a Pediatric Rheumatology Cohort

Chace Mitchell et al. ACR Open Rheumatol. .

Abstract

Objective: To investigate the association between demographic characteristics, disease characteristics, the number of rituximab (RTX) rounds, and concurrent immunosuppression on B cell level repletion following RTX therapy.

Methods: A retrospective chart review of 112 children who met inclusion criteria and were treated with RTX at a single institution was performed. Demographic, clinical, and laboratory data were extracted and compared. CD19 levels were reviewed at 6 and 12 months post-RTX with depletion defined as fewer than 10 cells/μL and complete repopulation to normal levels defined as 170 cells/μL or more.

Results: Among patients with CD19 levels, 48% of patients remained depleted at 6 months, 89% were repleted with 10 cells/μL or more by 12 months, and 46% remained below normal levels at 12 months following infusion. There was no significant association between the number of RTX rounds or underlying disease and persistent depletion below normal levels at 12 months following RTX infusion. Depletion at 6 months was associated with a 79% chance of persistent depletion below normal levels at 12 months. The association between concurrent cyclophosphamide (CYC) and repletion of 10 cells/μL or more at 6 (P = 0.091) and 12 months (P = 0.087) trended toward significance with no significant association between CYC and persistent depletion below normal levels.

Conclusion: RTX therapy for pediatric rheumatic diseases is well-tolerated and results in variable repletion and normalization of B cell numbers at 6 and 12 months. B cell repletion in children is variable and independent of underlying disease and of the number of RTX infusions.

PubMed Disclaimer

References

    1. Bernhardt MB, De Guzman MM, Grimes A, Kirk S, Nelson S, Bergsbaken J, et al. Rapid infusion of rituximab is well tolerated in children with hematologic, oncologic, and rheumatologic disorders. Pediatr Blood Cancer 2018;65. - PubMed
    1. Perugino CA, Stone JH. Treatment of IgG4‐related disease: current and future approaches. Z Rheumatol 2016;75:681–6. - PMC - PubMed
    1. Mahmoud I, Jellouli M, Boukhris I, Charfi R, Ben Tekaya A, Saidane O, et al. Efficacy and safety of rituximab in the management of pediatric systemic lupus erythematosus: a systematic review. J Pediatr 2017;187:213–9.e2. - PubMed
    1. Brito‐Zerón P, Bosch X, Ramos‐Casals M, Stone JH. IgG4‐related disease: advances in the diagnosis and treatment. Best Pract Res Clin Rheumatol 2016;30:261–78. - PubMed
    1. Parodi E, Nobili B, Perrotta S, Rosaria Matarese SM, Russo G, Licciardello M, et al. Rituximab (anti‐CD20 monoclonal antibody) in children with chronic refractory symptomatic immune thrombocytopenic purpura: efficacy and safety of treatment. Int J Hematol 2006;84:48–53. - PubMed

LinkOut - more resources